The expression level of ARF and p53 in AML patients, and their relation to patients' outcome
Abstract Background Acute myeloid leukemia (AML) is a cancer of hematopoietic progenitors characterized by gene mutations. The most popular deregulations are mutation and altered expression in the p53 gene, which is considered the guardian of the genome. Its activity is controlled by regulatory gene...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2023-03-01
|
| Series: | Egyptian Journal of Medical Human Genetics |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43042-023-00410-4 |
| _version_ | 1797853775667396608 |
|---|---|
| author | Reem Nabil Samar S. Elshazly Naglaa M. Hassan Hend A. Nooh |
| author_facet | Reem Nabil Samar S. Elshazly Naglaa M. Hassan Hend A. Nooh |
| author_sort | Reem Nabil |
| collection | DOAJ |
| description | Abstract Background Acute myeloid leukemia (AML) is a cancer of hematopoietic progenitors characterized by gene mutations. The most popular deregulations are mutation and altered expression in the p53 gene, which is considered the guardian of the genome. Its activity is controlled by regulatory genes, e.g., alternate open reading frame (ARF), whose defects could affect p53 activity. Aim To study the effect of altered expression of p53 and ARF genes in de novo AML patients and correlate the results to the patients’ characteristics and outcomes. Methods Expression levels of p53 and ARF were assessed in 96 AML adult patients compared to 20 healthy controls using quantitative reverse-transcription PCR (RT-qPCR). Results There was significant up-regulation of p53 [77.6 (3.8–9528.3)] compared to controls [1.031 (0.210–9.051)], p < 0.001]. The expression level of ARF was significantly upregulated [6.2 (0.5–964.0)] compared to controls [0.854 (0.357–2.519), p < 0.001]. All of the low ARF expressers had low p53 overexpression, 61.1% of patients with high ARF expression had high p53 over-expression, and 38.9% with high ARF expression had low p53 over-expression (p < 0.001). ARF expression shows a trend of association with FLT3 mutation, as 89.3% with FLT3 mutation have high ARF expression (p = 0.080). Low p53 over-expression was seen in 77% of APL patients, while high p53 expression was associated with non-APL (p = 0.040). The median DFS of mutant NPM1 patients was higher than wild NPM1 (46.15 vs. 5.89 days, p = 0.045). Patients aged ≤ 50 years had better OS and DFS than those > 50 (p = 0.05, p = 0.035, respectively).There were no significant statistical associations between DFS and p53, ARF, and FLT3 mutations. Conclusion The p53 and ARF genes are overexpressed in de novo AML patients and they are interrelated. low p53 overexpression is associated with APL phenotype and t(15;17) and patients with t(15;17) had slightly better survival than patients with negative t(15;17) (p = 0.061). AML patients with mutated NPM1 had better DFS than wild NPM1 (p = 0.045). p53 pathway regulation can occur by many alternative ways rather than gene mutation. |
| first_indexed | 2024-04-09T19:55:06Z |
| format | Article |
| id | doaj.art-43c28364b59b4d0cb88326a3a87b9786 |
| institution | Directory Open Access Journal |
| issn | 2090-2441 |
| language | English |
| last_indexed | 2024-04-09T19:55:06Z |
| publishDate | 2023-03-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Egyptian Journal of Medical Human Genetics |
| spelling | doaj.art-43c28364b59b4d0cb88326a3a87b97862023-04-03T05:29:39ZengSpringerOpenEgyptian Journal of Medical Human Genetics2090-24412023-03-0124111110.1186/s43042-023-00410-4The expression level of ARF and p53 in AML patients, and their relation to patients' outcomeReem Nabil0Samar S. Elshazly1Naglaa M. Hassan2Hend A. Nooh3Clinical Pathology Department, National Cancer Institute, Cairo UniversityClinical Pathology Department, National Cancer Institute, Cairo UniversityClinical Pathology Department, National Cancer Institute, Cairo UniversityClinical Pathology Department, National Cancer Institute, Cairo UniversityAbstract Background Acute myeloid leukemia (AML) is a cancer of hematopoietic progenitors characterized by gene mutations. The most popular deregulations are mutation and altered expression in the p53 gene, which is considered the guardian of the genome. Its activity is controlled by regulatory genes, e.g., alternate open reading frame (ARF), whose defects could affect p53 activity. Aim To study the effect of altered expression of p53 and ARF genes in de novo AML patients and correlate the results to the patients’ characteristics and outcomes. Methods Expression levels of p53 and ARF were assessed in 96 AML adult patients compared to 20 healthy controls using quantitative reverse-transcription PCR (RT-qPCR). Results There was significant up-regulation of p53 [77.6 (3.8–9528.3)] compared to controls [1.031 (0.210–9.051)], p < 0.001]. The expression level of ARF was significantly upregulated [6.2 (0.5–964.0)] compared to controls [0.854 (0.357–2.519), p < 0.001]. All of the low ARF expressers had low p53 overexpression, 61.1% of patients with high ARF expression had high p53 over-expression, and 38.9% with high ARF expression had low p53 over-expression (p < 0.001). ARF expression shows a trend of association with FLT3 mutation, as 89.3% with FLT3 mutation have high ARF expression (p = 0.080). Low p53 over-expression was seen in 77% of APL patients, while high p53 expression was associated with non-APL (p = 0.040). The median DFS of mutant NPM1 patients was higher than wild NPM1 (46.15 vs. 5.89 days, p = 0.045). Patients aged ≤ 50 years had better OS and DFS than those > 50 (p = 0.05, p = 0.035, respectively).There were no significant statistical associations between DFS and p53, ARF, and FLT3 mutations. Conclusion The p53 and ARF genes are overexpressed in de novo AML patients and they are interrelated. low p53 overexpression is associated with APL phenotype and t(15;17) and patients with t(15;17) had slightly better survival than patients with negative t(15;17) (p = 0.061). AML patients with mutated NPM1 had better DFS than wild NPM1 (p = 0.045). p53 pathway regulation can occur by many alternative ways rather than gene mutation.https://doi.org/10.1186/s43042-023-00410-4AMLP53 geneARF geneGene expression |
| spellingShingle | Reem Nabil Samar S. Elshazly Naglaa M. Hassan Hend A. Nooh The expression level of ARF and p53 in AML patients, and their relation to patients' outcome Egyptian Journal of Medical Human Genetics AML P53 gene ARF gene Gene expression |
| title | The expression level of ARF and p53 in AML patients, and their relation to patients' outcome |
| title_full | The expression level of ARF and p53 in AML patients, and their relation to patients' outcome |
| title_fullStr | The expression level of ARF and p53 in AML patients, and their relation to patients' outcome |
| title_full_unstemmed | The expression level of ARF and p53 in AML patients, and their relation to patients' outcome |
| title_short | The expression level of ARF and p53 in AML patients, and their relation to patients' outcome |
| title_sort | expression level of arf and p53 in aml patients and their relation to patients outcome |
| topic | AML P53 gene ARF gene Gene expression |
| url | https://doi.org/10.1186/s43042-023-00410-4 |
| work_keys_str_mv | AT reemnabil theexpressionlevelofarfandp53inamlpatientsandtheirrelationtopatientsoutcome AT samarselshazly theexpressionlevelofarfandp53inamlpatientsandtheirrelationtopatientsoutcome AT naglaamhassan theexpressionlevelofarfandp53inamlpatientsandtheirrelationtopatientsoutcome AT hendanooh theexpressionlevelofarfandp53inamlpatientsandtheirrelationtopatientsoutcome AT reemnabil expressionlevelofarfandp53inamlpatientsandtheirrelationtopatientsoutcome AT samarselshazly expressionlevelofarfandp53inamlpatientsandtheirrelationtopatientsoutcome AT naglaamhassan expressionlevelofarfandp53inamlpatientsandtheirrelationtopatientsoutcome AT hendanooh expressionlevelofarfandp53inamlpatientsandtheirrelationtopatientsoutcome |